Litigation Details for Par Pharmaceutical, Inc. v. Hospira, Inc. (D. Del. 2017)
✉ Email this page to a colleague
Par Pharmaceutical, Inc. v. Hospira, Inc. (D. Del. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-07-13 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | |
| Jury Demand | None | Referred To | |
| Patents | 9,119,876; 9,295,657 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Par Pharmaceutical, Inc. v. Hospira, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Par Pharmaceutical, Inc. v. Hospira, Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-06-04 | 189 | Order - -Memorandum and Order | expiration of Par’s patents covering Adrenalin®, U.S. Patent Nos. 9,119,876 (“the ’876 patent”) and 9,295,657…,657 (“the ’657 patent”) (together, “the Patents-in-Suit”) (Exs. 1-2). Par contends that Hospira’s ANDA…contention that if a patent describes only a single embodiment, the claims of the patent must be construed…112 of the Patent Act requires that the claims themselves set forth the limits of the patent grant, but… ANDA Product infringes the Patents-in-Suit under 35 U.S.C. § 271(e)(2), and that the manufacture, use | External link to document |
| 2019-06-04 | 190 | Order - -Memorandum and Order | expiration of Par’s patents covering Adrenalin®, U.S. Patent Nos. 9,119,876 (“the ’876 patent”) and 9,295,657…9,295,657 (“the ’657 patent”) (together, “the Patents-in- Suit”) (D.I. 1, Exs. 1-2). The patents-in-suit are …letter request for sanctions (D.I. 124). This is a patent infringement case arising under the Hatch-Waxman…the conditions specified by claims 12-19 of the patents-in-suit.” D.I. 54. While the parties were…13 July 2017 1:17-cv-00944-JFB-SRF Patent - Abbreviated New Drug Application(ANDA) | External link to document |
| 2019-06-06 | 191 | expiration of Par’s patents covering Adrenalin®, U.S. Patent Nos. 9,119,876 (“the ’876 patent”) and 9,295,657…,657 (“the ’657 patent”) (together, “the Patents-in-Suit”) (D.I. 1, Exs. 1- 2). Par alleges that Hospira…509 U.S. 579, 597 (1993) (D.I. 149).1 This is a patent infringement case arising under the Hatch-Waxman…Hospira’s ANDA Product infringes the Patents-in-Suit under 35 1 Also pending is a request for oral argument…importation of Hospira’s ANDA Product will infringe the Patents-in-Suit under 35 U.S.C. §§ 271(a), (b), and/or | External link to document | |
| 2019-06-21 | 197 | Order - -Memorandum and Order | ;876 patent”) and 9,295,657 (“the ‘'''657 patent") (together, the "patents-in-suit…expiration of the patents-in-suit. In its complaint, Par Pharma alleges infringement of U.S. Patent Nos. 9,119,876… four additional patent applications claiming priority to one of the asserted patents to show that “the…Claim Term “About.” D.I. 193. This is an action for patent infringement under the Hatch-Waxman Act, 21 U.…the subsequent related prosecution of additional patents to assert that the term “about” refers to a particular | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
